Episode 256: Managing Hodgkin Lymphoma in 2026

Chadi sits down with Dr. Sairah Ahmed just ahead of the ASH Annual Meeting for a comprehensive deep dive into the state of Hodgkin Lymphoma management in 2026. Dr. Ahmed walks through how clinicians should interpret the newest data releases, revisits whether histologic subtyping still influences decision-making in an era increasingly shaped by biomarkers, and details her practical framework for approaching patients with stage I/II disease—including when and how radiation therapy still plays a meaningful role. She further explores the strength and limitations of interim PET, whether treatment should truly pivot based on those scans, and how nivolumab is now being deployed across frontline, relapsed/refractory, and post-transplant settings. Rounding out the discussion, Dr. Ahmed outlines how she manages advanced-stage disease with particular attention to insights and implications from SWOG S1826, highlights immune-related toxicities clinicians must watch for, clarifies the evolving role of autologous transplant and the preferred sequence of prior therapies, and offers an inside look at the most important agents and strategies moving through the Hodgkin Lymphoma pipeline.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA